These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26330547)

  • 1. Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
    Peng Z; Li Z; Gao J; Lu M; Gong J; Tang ET; Oliner KS; Hei YJ; Zhou H; Shen L
    Mol Cancer Ther; 2015 Nov; 14(11):2634-41. PubMed ID: 26330547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.
    Chaudhary SP; Kwak EL; Hwang KL; Lennerz JK; Corcoran RB; Heist RS; Russo AL; Parikh A; Borger DR; Blaszkowsky LS; Faris JE; Murphy JE; Azzoli CG; Roeland EJ; Goyal L; Allen J; Mullen JT; Ryan DP; Iafrate AJ; Klempner SJ; Clark JW; Hong TS
    Oncologist; 2020 Nov; 25(11):e1691-e1700. PubMed ID: 32820577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
    Catenacci DV; Ang A; Liao WL; Shen J; O'Day E; Loberg RD; Cecchi F; Hembrough T; Ruzzo A; Graziano F
    Cancer; 2017 May; 123(6):1061-1070. PubMed ID: 27926778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.
    An X; Wang F; Shao Q; Wang FH; Wang ZQ; Wang ZQ; Chen C; Li C; Luo HY; Zhang DS; Xu RH; Li YH
    Cancer; 2014 Mar; 120(5):675-82. PubMed ID: 24804300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET expression and amplification in patients with localized gastric cancer.
    Janjigian YY; Tang LH; Coit DG; Kelsen DP; Francone TD; Weiser MR; Jhanwar SC; Shah MA
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1021-7. PubMed ID: 21393565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
    Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
    Janjigian YY; Werner D; Pauligk C; Steinmetz K; Kelsen DP; Jäger E; Altmannsberger HM; Robinson E; Tafe LJ; Tang LH; Shah MA; Al-Batran SE
    Ann Oncol; 2012 Oct; 23(10):2656-2662. PubMed ID: 22689179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.
    Yang Y; Wang C; Dai C; Liu X; Li W; Huang M; Zhao X; Ji D; Li J; Guo W
    Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):547-557. PubMed ID: 33693450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
    Shah MA; Kang YK; Thuss-Patience PC; Ohtsu A; Ajani JA; Van Cutsem E; Hoersch S; Harle-Yge ML; de Haas SL
    Gastric Cancer; 2019 Jul; 22(4):803-816. PubMed ID: 30706247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
    Shan L; Ying J; Lu N
    Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma.
    Liao JB; Lee HP; Fu HT; Lee HS
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):374-382. PubMed ID: 27753660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.
    Lee J; Seo JW; Jun HJ; Ki CS; Park SH; Park YS; Lim HY; Choi MG; Bae JM; Sohn TS; Noh JH; Kim S; Jang HL; Kim JY; Kim KM; Kang WK; Park JO
    Oncol Rep; 2011 Jun; 25(6):1517-24. PubMed ID: 21424128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MET amplification as a potential therapeutic target in gastric cancer.
    Kawakami H; Okamoto I; Arao T; Okamoto W; Matsumoto K; Taniguchi H; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K; Yamada Y
    Oncotarget; 2013 Jan; 4(1):9-17. PubMed ID: 23327903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET in gastric cancer--discarding a 10% cutoff rule.
    Metzger ML; Behrens HM; Böger C; Haag J; Krüger S; Röcken C
    Histopathology; 2016 Jan; 68(2):241-53. PubMed ID: 26033401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.
    Graziano F; Galluccio N; Lorenzini P; Ruzzo A; Canestrari E; D'Emidio S; Catalano V; Sisti V; Ligorio C; Andreoni F; Rulli E; Di Oto E; Fiorentini G; Zingaretti C; De Nictolis M; Cappuzzo F; Magnani M
    J Clin Oncol; 2011 Dec; 29(36):4789-95. PubMed ID: 22042954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.